Hideaki Kaneto

Summary

Affiliation: Osaka University
Country: Japan

Publications

  1. request reprint
    Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka T, Matsuhisa M, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med. 2004;10:1128-32 pubmed
    ..These data indicate that the JNK pathway is critically involved in diabetes and that the cell-permeable JNK-inhibitory peptide may have promise as a new therapeutic agent for diabetes. ..
  2. request reprint
    Kaneto H, Matsuoka T, Nakatani Y, Miyatsuka T, Matsuhisa M, Hori M, et al. A crucial role of MafA as a novel therapeutic target for diabetes. J Biol Chem. 2005;280:15047-52 pubmed
    ..These results suggest a crucial role of MafA as a novel therapeutic target for diabetes. ..
  3. Kaneto H, Matsuoka T, Kawashima S, Yamamoto K, Kato K, Miyatsuka T, et al. Role of MafA in pancreatic beta-cells. Adv Drug Deliv Rev. 2009;61:489-96 pubmed publisher
    ..These results suggest that MafA plays a crucial role in pancreatic beta-cells and could be a novel therapeutic target for diabetes. ..
  4. request reprint
    Kaneto H, Matsuoka T, Katakami N, Matsuhisa M. Combination of MafA, PDX-1 and NeuroD is a useful tool to efficiently induce insulin-producing surrogate beta-cells. Curr Med Chem. 2009;16:3144-51 pubmed
    ..The combination of MafA, PDX-1 and NeuroD markedly induces insulin biosynthesis in various non-beta-cells and thereby is a useful tool to efficiently induce insulin-producing surrogate beta-cells. ..
  5. request reprint
    Kaneto H, Matsuoka T, Miyatsuka T, Kawamori D, Katakami N, Yamasaki Y, et al. PDX-1 functions as a master factor in the pancreas. Front Biosci. 2008;13:6406-20 pubmed
    ..Thus, it is likely that alteration of such transcription factors explains, at least in part, the molecular mechanism for beta-cell glucose toxicity found in diabetes. ..